Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996892 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 1
- Development phase
- 178
- Enrollment target
NCT00996892 is a Phase 1 study that was terminated before completion, run by Genentech. The registered enrollment target is 178 participants.
The verdict
NCT00996892, a Phase 1 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 178 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase Ib dose-escalation study designed to assess the safety, tolerability and pharmacokinetics of oral dosing of cobimetinib and pictilisib administered in combination in patients with locally advanced or metastatic solid tumors.
Interventions
- DRUG Cobimetinib
- DRUG Pictilisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996892
The ClinicalTrials.gov registry entry for NCT00996892 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cobimetinib is the first listed.
NCT00996892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00996892 about?
NCT00996892 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors". This is an open-label, multicenter, Phase Ib dose-escalation study designed to assess the safety, tolerability and pharmacokinetics of oral dosing of cobimetinib and pictilisib administered in combination in patients with locally advanced or metastatic solid tumors.
What is the current status of trial NCT00996892?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2009-11. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00996892?
The interventions under investigation include: Cobimetinib (DRUG), Pictilisib (DRUG).
Who is sponsoring clinical trial NCT00996892?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.